O'Kane Kieran 4

What happened

• Kieran O'Kane, Chief Commercial Officer of Biodesix (BDSX), had 1,600 restricted stock units (RSUs) convert to common stock on 2026-02-09. Per the filing, 1,600 shares were used to satisfy tax withholding (reported as dispositions of 1,527 and 73 shares), and on 2026-02-10 O'Kane sold 584 shares in the open market at $10.08 per share, generating $5,889 in proceeds.
• These were not purchases (not a bullish signal): the primary activity was vesting of RSUs and routine sales/withholding related to taxes.

Key details

• Transaction dates and prices:
  • 2026-02-09: Conversion/settlement of 1,600 RSUs into shares (derivative exercise/conversion).
  • 2026-02-09: 1,527 shares and 73 shares were recorded as disposed (withholding/surrender) in connection with the RSU settlement (reported with $0 proceeds).
  • 2026-02-10: Open-market sale of 584 shares at $10.08 each, proceeds $5,889.
• Shares owned after transaction: Not specified in the provided excerpt of the filing.
• Notable footnotes:
  • F1/F4/F6: These were RSUs (each RSU equals one share) that vested according to previously disclosed schedules (some vested quarterly since Feb 8, 2022; others on annual schedule from Feb 8, 2023).
  • F2/F3: Shares were automatically sold/withheld to cover taxes upon vesting. The filing notes sales by the issuer's broker at prices ranging $9.94–$10.21; the reported $10.08 is a weighted average for the reported sale(s).
  • F5: Share counts were adjusted for a 1-for-20 reverse stock split effective Sept 15, 2025.
• Timeliness: Reported on 2026-02-11 for transactions on 2026-02-09/10 — the Form 4 was filed within the standard two-business-day window (not reported late).

Context

• These entries reflect RSU vesting and routine tax-withholding-related dispositions. For derivative/RSU activity, the filing shows conversion of awards into shares and immediate withholding/sales to cover tax obligations (i.e., a cashless/net settlement), not an independent investment decision.